Sanofi: Deutsche Bank upgrades stock
(CercleFinance.com) - Deutsche Bank announced on Friday that it has upgraded on Sanofi shares from 'sell' to 'hold' following yesterday's 'solid' Q4 results.
The analyst, who is raising his target price for the stock from E85 to E100 (cp: E104.6, +1%), cites a publication that points to a business in "rather good shape", with robust growth expected over the medium term and limited risks, apart from those still surrounding the completion of potential mergers and acquisitions (M&A).
The broker believes that the launch of share buy-backs reduces the likelihood of future buy-backs, while also pointing to softer competition and the commercial momentum of Dupixent, which it sees as a good omen in view of its recent launch in the treatment of COPD.
The broker believes that all these elements leave "fewer reasons to be clearly cautious" on the stock.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
The analyst, who is raising his target price for the stock from E85 to E100 (cp: E104.6, +1%), cites a publication that points to a business in "rather good shape", with robust growth expected over the medium term and limited risks, apart from those still surrounding the completion of potential mergers and acquisitions (M&A).
The broker believes that the launch of share buy-backs reduces the likelihood of future buy-backs, while also pointing to softer competition and the commercial momentum of Dupixent, which it sees as a good omen in view of its recent launch in the treatment of COPD.
The broker believes that all these elements leave "fewer reasons to be clearly cautious" on the stock.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.